12 үр дүн
FIELD OF THE INVENTION
The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the
BACKGROUND OF THE INVENTION
This invention relates to gene therapy. More particularly, this invention relates to a plasmid system for increased expression of vascular endothelial growth factor (VEGF) under hypoxia conditions. The plasmid system can be used for treating ischemic disease in a person
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is in the fields of treatment for cardiac disease, treatment of ulcers, gene therapy and molecular imaging.
2. Background of the Invention
Coronary artery disease is the leading cause of morbidity and mortality in the Western
FIELD
The present disclosure is generally directed to inhibitors of the Hypoxia Inducible Factor (HIF) pathway and their methods of use including anti-tumor therapies and disorders leading to ischemia (stroke, ischemic heart disease etc.) as well as non-cancerous angiogenic diseases (rheumatoid
BACKGROUND OF THE INVENTION
The present invention generally relates to pyridone substituted benzothiazole compounds that are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A.sub.2A -receptor and a high selectivity to the A.sub.1 - and
BACKGROUND OF THE INVENTION
Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
BACKGROUND OF THE INVENTION
Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
TECHNICAL FIELD
The present invention relates to methods of treating a subject suffering from an ischemic condition and of preventing an ischemia-reperfusion injury in a subject suffering from an ischemic condition. The ischemic condition is especially but not exclusively ischemic heart disease and